CD8A and neoplasm: Against solid hMUC1-B16.F10 tumors, GT-00AxIL15 monotherapy did not inhibit primary tumor growth, but the expected PD effects on TILs, i.e., significant expansion of NK and CD8+ T cells in the tumor compared to periphery, were observed, leading to anti-tumor effects in combination with anti-PD-L1.